METAVIA INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- METAVIA INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.42M, a 40200.00% increase year-over-year.
- METAVIA INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $2.00K.
- METAVIA INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $6.00K.
- METAVIA INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $1.00K.
- METAVIA INC. stock issued during period, value, stock options exercised for fiscal 2025 was $6.00K, a 500.00% increase from fiscal 2024.
- METAVIA INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.00K, a 99.99% decline from fiscal 2023.
- METAVIA INC. stock issued during period, value, stock options exercised for fiscal 2023 was $7.18M, a 29.10% increase from fiscal 2022.
- METAVIA INC. stock issued during period, value, stock options exercised for fiscal 2022 was $5.56M, a 4738.26% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.42M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $2.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $6.00K 10-K · filed 2026-03-26 | |
| 2025-06-30 | $6.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $1.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $7.18M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $5.40M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $1.44M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $5.56M 10-K · filed 2024-03-28 | |
| 2021-12-31 | $115.00K 10-K · filed 2023-03-30 | |
| 2021-06-30 | $72.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $53.00K 10-K · filed 2022-03-31 | |
| 2020-03-31 | $53.00K 10-Q · filed 2021-11-15 | |
| 2019-12-31 | $1.00K 10-K · filed 2021-04-15 | |
| 2018-12-31 | $84.00K 10-K · filed 2019-03-18 | |
| 2018-09-30 | $61.00K 10-Q · filed 2019-11-08 | $84.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $51.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-03-31 | $23.00K 10-Q · filed 2019-11-08 | $61.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $41.00K 10-K · filed 2019-03-18 |
| 2017-09-30 | $28.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $10.00K 10-Q · filed 2018-11-08 | |
| 2017-03-31 | $3.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |